BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, today released an update from its Chairman, Richard Staelin, PhD, detailing sales growth, strategic initiatives, and operational progress. The company, which focuses on non-opioid pain management solutions, reported a small profit for calendar year 2025 following disciplined cost control measures, including office relocation and staff reductions.
According to the update, BioElectronics has launched targeted advertising campaigns aimed at medical professionals and healthcare providers to expand clinical awareness of its RecoveryRx device among surgeons, pain specialists, and rehabilitation providers. Additionally, the company has intensified consumer-focused social media advertising targeting Generation X consumers to promote drug-free solutions for chronic musculoskeletal pain. These efforts have contributed to an increase in monthly sales across both over-the-counter and professional markets.
In a significant strategic development, BioElectronics announced progress with its distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, and Electrome has placed its first purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This milestone provides another pathway to increase consumer awareness and access to the company's FDA-cleared, drug-free pain therapy products.
The company also continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The objective is to participate in a postoperative clinical study that may support future qualification for reimbursement under the federal NO PAIN Act initiative, which BioElectronics believes represents a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor that allegedly breached contractual obligations. The company remains committed to protecting its intellectual property and shareholder interests and anticipates providing updates as developments occur.
Chairman Staelin expressed optimism about the growing interest in non-drug pain management solutions and the long-term potential of the company's technology platforms. He stated, "We believe BioElectronics is well positioned within the evolving electroceutical and non-opioid pain management markets, and we intend to continue advancing initiatives that support sustainable growth." The company appreciates shareholder support as it executes its strategic initiatives and works to build long-term value.
